CCL2 and Hepatic steatosis: Indeed, pharmacological antagonist of CCR2 reduced liver steatosis in obese and diabetic mice (db/db), and CCL2 deficiency reduced the accumulation of hepatic triglycerides in HFD and db/db mice [48, 50].